Improving outcome for patients after osteoporotic femoral fracture

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN33363553

Enrollment

450

Registered

2006-07-11

Start date

2006-09-01

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis Musculoskeletal Diseases Osteoporosis

Interventions

Patients will be randomised to one of three groups: Group one will receive weekly alendronate plus vitamin D and calcium. Group two will receive daily teriparatide plus vitamin D and calcium. Group th

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with acute, traumatic trochanteric or supracondylar femoral fractures who are 55 or older presenting with fragility fractures.

Exclusion criteria

Exclusion criteria: 1. Patients with open fractures, pathological fractures, who have a 'floating knee', associated patellar fracture or simultaneous bilateral fracture. 2. Patients with known metabolic bone disease, rheumatoid arthritis and patients with chronic renal failure. 3. Patients on steroids, strontium, bisphosphonates and parathyroid hormone. 4. Patients with dementia.

Design outcomes

Primary

Measure	Time frame
The difference between the baseline Johanson Hip Rating Questionnaire (HRQ) score and the HRQ score at six weeks. A target difference of seven to ten points will be considered significant.	—

Secondary

Measure	Time frame
Pain and function.	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026